Silymarin kezelés immunmoduláns hatása krónikus alkoholos májbetegségben.

Translated title of the contribution: Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases

G. Deák, G. Müzes, I. Láng, V. Niederland, K. Nékám, R. Gonzalez-Cabello, P. Gergely, J. Fehér

Research output: Contribution to journalReview article

9 Citations (Scopus)


The effects of the hepatoprotective, antioxidant drug silymarin (Legalon) on some cellular immune parameters of patients with histologically proven chronic alcoholic liver disease were studied in a six month double blind study. The lectin induced proliferative activity of the lymphocytes got enhanced, the originally low T cell percentage and the originally high CD8+ cell percentage have been normalized, the antibody-dependent and natural cytotoxicity of the lymphocytes decreased during silymarin therapy. All these changes were significant, while in the placebo group no significant changes occurred, except for a moderate elevation of the T cell percentage. Thus, the immunomodulatory activity of silymarin might be involved in the hepatoprotective action of the drug and improves the depressed immunoreactivity of the patients.

Original languageHungarian
Pages (from-to)1291-1292, 1295
JournalOrvosi hetilap
Issue number24
Publication statusPublished - Jun 17 1990


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Deák, G., Müzes, G., Láng, I., Niederland, V., Nékám, K., Gonzalez-Cabello, R., Gergely, P., & Fehér, J. (1990). Silymarin kezelés immunmoduláns hatása krónikus alkoholos májbetegségben. Orvosi hetilap, 131(24), 1291-1292, 1295.